Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegenerative Ocular Diseases tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Pacira Appoints Frank D Lee as Chief Executive Officer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Therini Bio Announces Interim Results from the Phase 1 Trial of THN391 for the Potential Treatment of Dementia tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Therini Bio, Inc., a South San Francisco, CA-based vascular biology company, raised 17m in seed extension round of financing.
The round was co-led by SV Health Investors’ Impact Medicine Fund, MRL Ventures, and Sanofi Ventures who join existing investors including the Dementia Discovery Fund and Dolby Family Ventures, as well as new investor, Foundation for a Better World. With the closing of the financing Dr. Christine Brennan, PhD from MRL Ventures and Dr. Jim Trenkle, PhD from Sanofi Ventures have joined the Therini board of directors.
The company intends to use the capital to accelerate the development of its lead program – a monoclonal antibody against fibrin – towards the clinic for patients with inflammatory conditions associated with vascular damage.